Lab-Grown Brain Tumor Organoids Build Their Own Blood Vessels and Scaffolding

Glioblastoma remains one of the most feared diagnoses in medicine. Even with aggressive surgery, radiation, and chemotherapy, patients with this aggressive brain tumor typically survive only twelve to fifteen months, and few live beyond two to three years. A central reason for these dismal outcomes is that the tumor’s microenvironment—a tangled landscape of malformed blood vessels, remodeled extracellular matrix, and invasive stem-like cells at the tumor’s edge—has been extraordinarily difficult to recreate in the laboratory. Now, a team of bioengineers reports a strikingly simple solution: grow glioblastoma organoids without any added scaffold or serum, and let the tumor cells build their own supporting architecture from scratch. The result is a self-assembling model that grows its own neurovascular-like structures and extracellular matrix, closely mirroring what clinicians see in patient tissue.

The study, published in Bioengineering & Translational Medicine, comes from researchers at The University of Alabama who set out to strip away the confounding ingredients that have long plagued organoid modeling. Conventional glioblastoma organoids are typically made by embedding glioblastoma stem cells in animal-derived matrix hydrogels such as Matrigel and differentiating them with undefined serum supplements. Those ingredients provide structure, but they also mask the cells’ intrinsic capacity to fabricate their own microenvironment, introduce batch-to-batch variability, and make it nearly impossible to know whether any vessel-like structure observed in a dish formed because of the model or in spite of it. The new approach removes the exogenous matrix entirely, relying instead on controlled geometry and a sublethal level of fluid shear stress to coax the cells into organizing themselves.

To judge whether the resulting organoids were biologically faithful, the team first needed a rigorous clinical benchmark. They mined publicly available transcriptomic data from The Cancer Genome Atlas, curating a high-confidence subset of 35 patient cases spanning healthy brain tissue, low-grade glioma, and glioblastoma. Because the World Health Organization reclassified central nervous system tumors in 2021, shifting diagnosis toward molecular definitions, many older low-grade glioma cases would today be called glioblastoma. The researchers therefore subdivided the low-grade glioma cohort into molecular subgroups—those resembling normal tissue, those resembling glioblastoma, and a transitional group—effectively modernizing the clinical baseline. Principal component analysis revealed a clear developmental axis, and differential expression analysis defined a conserved glioma signature: upregulation of embryonic-like tissue growth programs and oxidative phosphorylation, paired with suppression of mature neuronal pathways, particularly GABA-ergic signaling. Crucially, network analysis identified VEGFA and fibronectin as central hubs linking vasculogenesis to collagen metabolism, confirming that glioma progression is underpinned by coordinated remodeling of neurovascular and matrix components.

With that baseline in hand, the team grew organoids from a patient-derived xenograft line called JX6, a classical-subtype glioblastoma carrying the amplified EGFR variant III mutation. Glioblastoma stem cells were first seeded into cell-repellent U-bottom plates to form spheroids of roughly 400 to 600 micrometers, then transferred to a stirred 100-milliliter bioreactor operating at a shear stress of about 0.5 pascals. No other media components, matrices, or scaffolds were added at any point. Under these conditions the organoids grew to four millimeters in diameter, and the researchers tracked their molecular development against the patient data across a unified five-stage scale. The comparison revealed a striking convergence: trajectories for capillary, venule, and large artery gene markers, along with astrocyte, fibroblast, and pericyte/smooth muscle cell signatures, all peaked in alignment with clinical benchmarks at the two-millimeter stage of organoid growth.

That two-millimeter milestone emerged as the heart of the study. Confocal imaging of organoids stained for the endothelial marker CD31 and the matrix proteins tenascin-C and fibronectin revealed a precise temporal cascade. Tiny 0.6-millimeter spheroids expressed essentially none of these markers. By one millimeter, tenascin-C—an anti-adhesive matrix protein associated with cell migration—appeared around the organoid core. At 1.5 millimeters, fibronectin was deposited peripherally and nascent endothelial clusters emerged. Only at two millimeters did fibronectin and CD31 significantly co-localize, indicating that the tumor cells first fabricate a fibronectin-rich scaffold and then recruit endothelial cells onto it—a matrix-primed sequence of vascular assembly that has been described in glioblastoma patients but rarely recapitulated in vitro.

The spatial architecture of the mature organoids proved equally faithful. Two-millimeter organoids displayed a distinct tri-zonal organization: an infiltrating rim rich in tenascin-C, a vascular-like area dominated by fibronectin and CD31, and a hypoxic, necrotic core. The rim’s thickness of roughly 153 to 180 micrometers sits just below the approximately 200-micrometer oxygen diffusion limit, defining a structurally coherent metabolic boundary. The vascular-like zone, spanning about 750 to 1,013 micrometers, contained the densest vessel branching and the tightest lumen spacing, echoing the weblike capillary beds of living tissue. Quantifying lumen sizes by minimum Feret diameter showed that most channels fell in the 5-to-10-micrometer range—the expected caliber of human capillaries—with larger structures matching arteriole and venule dimensions, and none exceeding 105 micrometers.

To test whether these structures were more than anatomical decoration, the researchers incubated organoids with a 3-kilodalton fluorescent dextran tracer, chosen because its size approximates temozolomide, the standard chemotherapy for glioblastoma. Multiphoton imaging of whole-mount cleared organoids showed clear tracer transport within capillary-like lumens of 9 to 12 micrometers in diameter, and the radial intensity gradients fit Fick’s second law of diffusion modeled in spherical coordinates, yielding an effective diffusion coefficient of about 0.15 square micrometers per second. That value is more than two orders of magnitude lower than measurements of 3-kilodalton dextran diffusion in the rat brain extracellular space, likely reflecting the densely packed protective rim, immature endothelial junctions, and the absence of internal hemodynamic shear stress. The authors note that human glioma tissue itself poses elevated diffusion resistance due to increased extracellular volume and tortuosity linked to tenascin-rich matrix deposition, so the comparison, while sobering, is not entirely discouraging.

The divergences that remain are informative rather than fatal. Organoids underexpressed proteoglycans involved in cell-matrix adhesion and diverged on arterial and large-vein markers, patterns the researchers attribute to the lack of controlled hemodynamic shear stress—the tangential force from blood flow that stabilizes endothelial identity in living vessels. Their proposed remedy is elegant: introduce internal perfusion via microfluidics at the one-to-1.5-millimeter stage, after the critical tenascin-C and fibronectin matrix has self-organized but before endothelial networks fully mature, while maintaining the existing bulk shear of roughly 0.5 pascals to support peripheral expansion. Such a system could push the organoids from modeling the anatomy of the tumor microenvironment toward a genuinely functional, human-centric platform for preclinical drug validation.

The therapeutic implications may be the most exciting part. Because the model reveals that glioblastoma stem cells actively prime their niche with an anti-adhesive-to-adhesive matrix switch—tenascin-C first, fibronectin second—to enable invasion and neovascularization, it nominates that scaffold as a drug target. High-throughput screening using these organoids could identify small molecules or antibodies that disrupt tenascin-C and fibronectin assembly, potentially weakening the tumor’s structural defenses and improving drug penetration across the blood-brain barrier. For a disease where nearly every experimental therapy has foundered on the same two obstacles—infiltration at the tumor margin and delivery across the vasculature—a reproducible, scaffold-free, human-derived model that recapitulates both processes autonomously represents a meaningful step forward. The organoids do not yet beat like a living brain, but they are, remarkably, building themselves.

Subject of Research: Matrix-free biomanufacturing of glioblastoma organoids that self-assemble neurovascular-like structures and extracellular matrix

Article Title: Exogenous matrix‐free biomanufacturing of glioblastoma organoids enables autonomous assembly of neurovascular‐like structures and extracellular matrix

Article References: Avera, A. D., Schnorbus, T. N., & Kim, Y. (2026). Exogenous matrix‐free biomanufacturing of glioblastoma organoids enables autonomous assembly of neurovascular‐like structures and extracellular matrix. Bioengineering & Translational Medicine, Article e70166. https://doi.org/10.1002/btm2.70166

Image Credits: AI Generated

DOI: 10.1002/btm2.70166

Keywords: glioblastoma, organoids, neurovascular unit, extracellular matrix, glioblastoma stem cells, tenascin-C, fibronectin, biomanufacturing, blood-brain barrier, drug screening, TCGA, bioreactor